This study provides evidence to support that EF24 may be a useful therapeutic reagent for the treatment of hepatocellular carcinoma and suggests that Src is a novel and promising therapeutic target in hepatocellular carcinoma. This evidence concerns the gene SRC and hepatocellular carcinoma.